
About Dedeepya Pharma
Dedeepya Pharma is a Healthcare company based in India. Pharmaceutical manufacturing and supply of affordable medicines for acute and chronic conditions in India. Its Indian entity Dedeepya Pharma Private Limited reported revenue of βΉ167 Cr. Dedeepya Pharma offers products and services including Ceftriaxone and Meropenem. Its focus areas include Pharmaceuticals, Drug Manufacturing, Specialty Pharmaceuticals and Medical Supplies.
Company details
Dedeepya Pharma is recognized as an emerging Indian pharmaceutical company that focuses on sustaining life and promoting healthcare through the provision of high-quality, effective, and affordable medicines for a broad spectrum of conditions. Products are thoroughly assessed for safety, quality, and efficacy to ensure they can be utilized with confidence across all stages of life. The company strives towards innovation in medicine to meet unmet needs in therapy areas while upholding values like commitment, passion, teamwork, and quality. Accessibility to these formulations is emphasized to contribute to better health outcomes in India.
- Headquarters India
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website dedeepyapharma.in
- Legal Name Dedeepya Pharma Pvt. Ltd
- Date of Incorporation 11 Dec, 2014
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹167 Cr
FY 2024 · +86% YoY
- Net Profit₹5.15 Cr
FY 2024 · 3% margin
- EBITDA₹8.96 Cr
FY 2024 · 5% margin
Associated legal entities of Dedeepya Pharma
Dedeepya Pharma operates through Dedeepya Pharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Dedeepya Pharma Private Limited CIN U24100TG2014PTC096778 | Active | 11 Dec 2014 | Hyderabad, Telangana | ₹167 Cr | 5 | View details |
Products & Services of Dedeepya Pharma
Dedeepya Pharma offers a comprehensive portfolio of products and services, including Ceftriaxone and Meropenem.
This product is manufactured as an injectable for treating bacterial infections and is supplied for use in critically ill patients.
This medication is provided in injection form for addressing severe infections and is included in the portfolio of supportive treatments.
Board of directors of Dedeepya Pharma Private Limited (Dedeepya Pharma)
Dedeepya Pharma Private Limited is the primary company behind Dedeepya Pharma. The board of Dedeepya Pharma Private Limited currently have 5 directors; the longest-serving is Mahidhar Reddy Dasari, appointed in 2014.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Mahidhar Reddy Dasari DIN 07031133 | Whole-time director | 11 Dec 2014 | 11 yrs 11 mo | Dedeepya Pharma Private Limited |
| Manjula Dasari DIN 07031139 | Whole-time director | 11 Dec 2014 | 11 yrs 11 mo | Dedeepya Pharma Private Limited |
| Varun Reddy Dasari DIN 07031141 | Managing Director | 11 Dec 2014 | 11 yrs 11 mo | Dedeepya Pharma Private Limited |
| Preeti Reddy Dasari DIN 07253245 | Director | 05 Aug 2015 | 11 yrs 3 mo | Dedeepya Pharma Private Limited |
| Niharika Reddy Kondakindi DIN 08637098 | Director | 30 Sep 2024 | 2 yrs 1 mo | Dedeepya Pharma Private Limited |
Financials of Dedeepya Pharma
Figures of Dedeepya Pharma Private Limited, the primary company behind Dedeepya Pharma, for FY 2024. Revenue was ₹167 Cr (+86% year on year). Net profit was ₹5.15 Cr (3% margin). EBITDA was ₹8.96 Cr (5% margin). Revenue has grown at a compounded annual rate of +75% over three years and +39% over five years.
- ₹167 CrRevenue · FY 2024 · +86% YoY
- ₹5.15 CrNet profit · 3% margin
- ₹8.96 CrEBITDA · 5% margin
- ₹1.50 CrPaid-up capital
- +75%Revenue CAGR, 3 years
- +39%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Dedeepya Pharma Private Limited are on its company page.
Detailed financial statements for Dedeepya Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Dedeepya Pharma
Dedeepya Pharma is headquartered in India.
The primary company behind Dedeepya Pharma, Dedeepya Pharma Private Limited, reported revenue of βΉ167 Cr for FY 2024, up 86% year on year.
Dedeepya Pharma is recognized as an emerging Indian pharmaceutical company that focuses on sustaining life and promoting healthcare through the provision of high-quality, effective, and affordable medicines for a broad spectrum of conditions. Products are thoroughly assessed for safety, quality, and efficacy to ensure they can be utilized with confidence across all stages of life. The company strives towards innovation in medicine to meet unmet needs in therapy areas while upholding values like commitment, passion, teamwork, and quality. Accessibility to these formulations is emphasized to contribute to better health outcomes in India.
Dedeepya Pharma offers Ceftriaxone and Meropenem.
Dedeepya Pharma operates through Dedeepya Pharma Private Limited.
The legal entities of Dedeepya Pharma currently have 5 directors, including Mahidhar Reddy Dasari, Manjula Dasari, Varun Reddy Dasari and others.